Drug Trial Radar · NCT00295594
Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.
Last checked: Nov 20, 2026Latest source record: Aug 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
627
Actual
Start
Mar 2005
Primary completion
Jun 2007
Study completion Jun 2007
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Feb 24, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy and safety of two regimens containing tacrolimus and minimal steroids together with either monoclonal anti-IL2R antibodies (daclizumab) or mycophenolate mofetil.
Conditions
- Liver Transplantation
Interventions
tacrolimusDrug
Immunosuppression
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of and time to first biopsy proven acute rejection which requires treatment within 3 months following transplantationTime frame: 3 months
Locations
41 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Ghent, Belgium
Site not named
Leuven, Belgium
Site not named
Liège, Belgium
Site not named
Copenhagen, Denmark
Site not named
Helsinki, Finland
Site not named
Bonn, Germany
Site not named
Erlangen, Germany
Site not named
Essen, Germany
Site not named
Hamburg, Germany
Site not named
Hanover, Germany
Site not named
Kiel, Germany
Site not named
Mainz, Germany
Site not named
Budapest, Hungary
Site not named
Bari, Italy
Site not named
Bergamo, Italy
Site not named
Milan, Italy
Site not named
Milan, Italy
Site not named
Naples, Italy
Site not named
Padova, Italy
Site not named
Palermo, Italy
Site not named
Udine, Italy
Site not named
Szczecin, Poland
Site not named
Wroclaw, Poland
Site not named
A Coruña, Spain
Site not named
Barcelona, Spain
Site not named
Córdoba, Spain
Site not named
Granada, Spain
Site not named
Madrid, Spain
Site not named
Madrid, Spain
Site not named
Madrid, Spain
Site not named
Murcia, Spain
Site not named
Pamplona, Spain
Site not named
Santiago, Spain
Site not named
Seville, Spain
Site not named
Valencia, Spain
Site not named
Gothenburg, Sweden
Site not named
Uppsala, Sweden
Site not named
Bern, Switzerland
Site not named
Zurich, Switzerland
Site not named
Leeds, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.